Biphasic lipid vesicles as a subcutaneous delivery system for protein antigens and CpG oligonucleotides.
One of the major drawbacks to the development of novel vaccines has been the lack of safe yet effective adjuvants. Biphasic lipid vesicles are formulations suitable for the delivery of proteins, peptides and oligo/polynucleotides. They constitute a new class of delivery system into which antigens and adjuvants can be incorporated. The purpose of these studies was to investigate the ability of biphasic lipid vesicles (Vaccine-Targeting Adjuvants--VTA) to induce immune responses to bacterial antigens and to enhance the adjuvant activity of CpG ODNs. Immunization of mice with bacterial antigen and CpG ODNs in saline was not as effective at inducing immune responses as formulation in VTA vesicles. Results showed that formulation of CpG ODN in VTA significantly enhanced its adjuvanticity.
Alcón
Valeria L
VL
College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK. S7N 5C9, Canada.
Baca-Estrada
Maria E
ME
Potter
Andrew
A
Babiuk
Lorne A
LA
Kumar
Praveen
P
Foldvari
Marianna
M
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D000941:Antigens / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D005079:Excipients; D005260:Female; D008055:Lipids / Q000008:administration & dosage*; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage*; D014612:Vaccines / Q000008:administration & dosage*
D000276:Adjuvants, Immunologic; D000941:Antigens; C408982:CPG-oligonucleotide; D005079:Excipients; D008055:Lipids; D009838:Oligodeoxyribonucleotides; D014612:Vaccines